β 2 -Glycoprotein I/IgA Immune Complexes

• DOI: 10.1161/circulationaha.116.025992
• Publication Date: 2017-03-02T02:00:20Z
• Authors: Manuel Serrano; José A. Martínez-...; Dolores Pérez; Florencio García; Oscar Cabrera; Daniel Pleguezuelo; Estela Paz-Artal; José M. Morales; Esther González; Antonio Serrano
• Keywords: Adult; Male; Thrombosis; Antigen-Antibody Complex; Middle Aged; Kidney Transplantation; Immunoglobulin A; 3. Good health; Cohort Studies; antibodies, antiphospholipid, autoantibodies, graft occlusion, vascular, immune complex diseases, kidney transplantation, thrombosis; 03 medical and health sciences; 0302 clinical medicine; Ciencias Biomédicas; 32 Ciencias Médicas; Predictive Value of Tests; beta 2-Glycoprotein I; Antibodies, Antiphospholipid; Humans; Female; Biomarkers; Aged; Autoantibodies; Follow-Up Studies

Background: Antiphospholipid syndrome is characterized by recurrent thrombosis and gestational morbidity in patients with antiphospholipid autoantibodies (aPLs). Predictive value of the presence aPLs low, new markers are necessary to identify aPL carriers at higher risk take preventive measures on them. The circulating immune complexes IgA bound β 2 -glycoprotein I (B2A-CIC) has been associated occurrence acute thrombotic events. In this work we study its possible predictive for appearance events who going undergo transplant surgery, a well-known trigger carriers. Methods: We performed follow-up based Magnum 12+12 Cohort received kidney (n=1339). Three groups were established: group 1 positive anti-β (aB2GP1) B2A-CIC (n=125); only aB2GP1 (n=240); control group, negative (n=974). Levels quantified immediately before surgery followed up 6 months. Results: 1, 46.4% experienced any type versus 10.4% ( P <0.001) 8.6% <0.001). incidence graft (31.2%) was significantly than that observed (3.3%, (2.6%, multivariate analysis, an independent variable experience posttransplant (hazard ratio, 6.72; 95% confidence interval, 4.81–9.37) and, prominently, 14.75; 9.11–23.89). No significant differences found between B2A-CIC–negative patients. Conclusions: predictor Patients experiencing if they positive. If patients, have same as group. Treatments prevent should focus B2A-CIC–positive